We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Eli Lilly and Company
Health Care · Pharmaceuticals
Structural read: incretin franchise (tirzepatide) is the single largest near-term revenue driver in pharma, with GLP-1 TAM estimates in the $100-150B range by early 2030s and LLY + $NVO splitting the duopoly. Capacity - not demand - has been the binding constraint; LLY has committed $50B+ cumulative capex across Indiana, North Carolina, and Europe to expand fill-finish and API.
Pipeline optionality from oral GLP-1 (orforglipron) and next-gen multi-agonists (retatrutide) extends the runway past tirzepatide LOE.
- Mounjaro + Zepbound combined run-rate scaling toward $30B+ as supply unlocks
- Orforglipron oral GLP-1 phase-3 readouts position LLY for the at-home segment $NVO cannot service with injectables
- Donanemab adds an Alzheimer's leg (Kisunla approved 2024) with no direct $BIIB-class competitor at scale
- $50B+ capex build is a moat: incretin manufacturing is the bottleneck, and CDMO partners ($CTLT, $TMO bioprocess) inherit spillover demand
- Compounded GLP-1 grey market and payer pushback on coverage compress realized price
- Pipeline single-point-of-failure: a tirzepatide safety signal or retatrutide failure resets the multiple
- ~30x forward P/E prices in flawless execution; any capacity slip or Medicare negotiation surprise asymmetric
- LOE clock on tirzepatide starts mid-2030s - pipeline must deliver to avoid a patent cliff
No major news in the last 7 days for LLY - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.